Our findings mechanistically reveal that combining 2-DG with cisplatin or PARP inhibitors will benefit HNSCC patients with KMT2D-inactivating mutations, providing an important epigenomic basis for designing clinical trials for this patient cohort. Here, KMT2D is linked to head and neck squamous cell carcinoma.